Toll-like receptor 5 agonist CBLB502 induces radioprotective effects in vitro

Tong Shi, Liqin Li, Guochao Zhou, Chen Wang, Xuejun Chen, Ruihua Zhang, Jianfu Xu, Xiaojing Lu, Hui Jiang, and Jisheng Chen

State Key Laboratory of NBC Protection for Civilian, Beijing 102205, China

Acta Biochim Biophys Sin 2017, 49: 487–495; doi: 10.1093/abbs/gmx034

CBLB502 derived from Salmonella flagellin is a novel agonist of Toll-like receptor 5 (TLR5). It has been shown that CBLB502 can exert high radioprotective efficacy on mice and primates from both GI and hematopoietic syndromes during whole-body irradiation with low toxicity and immunogenicity. However, no effective system has been used to investigate the protective effect of CBLB502 against irradiation and the related mechanism in vitro. In this study, we investigated the radioprotective properties of CBLB502 in HEK293-N-T cells constitutively expressing human TLR5 and NF-κB-dependent luciferase. HEK293-N-T cells were treated with different doses of CBLB502 prior to 60Co-γ ray irradiation. After irradiation, cell viability was real-time measured for 4 days by using the real-time cell analysis system. We found that CBLB502 was capable of efficiently maintaining the survival rate of irradiated HEK293-N-T cells. Then apoptotic cell death and cell cycle were detected by flow cytometry. The results showed that CBLB502 pre-treatment could reduce the apoptosis and promote the recovery of irradiated HEK293-N-T cells from G2-phase arrest in a dose-dependent manner. Our data indicated that CBLB502 has a direct radioprotective effect in vitro via anti-apoptosis and promotes cell cycle recovery. The method developed here could be an effective in vitro system to screen other TLR5-target radioprotectants like CBLB502.

CBLB502 improves the viability of irradiated cells

阅读原文: http://www.abbs.org.cn/arts.asp?id=4161

获取全文: abbs@sibs.ac.cn

相关论文:

1 An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models

2 Targeting Toll-like receptors: emerging therapeutics?

3 Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer

4 Structural Basis of TLR5-Flagellin Recognition and Signaling

5 The Yin and Yang of Toll-like receptors in cancer

6 Radiation enteropathy-pathogenesis, treatment and prevention

7 Cancer Radiosensitizers

8 Flagellin, a TLR5 Agonist, Reduces Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation Recipients While Enhancing Antiviral Immunity